老年局部晚期乳腺癌患者根治术前实施重组人血管内皮抑制素联合EC-T序贯新辅助化疗的疗效及安全性分析  

Efficacy and safety analysis of recombinant human endostatin combined with EC-T sequential neoadjuvant chemotherapy before radical resection of locally advanced breast cancer in elderly patients

作　　者：吴新妮 汤磊磊 Wu Xinni;Tang Leilei(Department of Thyroid and Breast Surgery,Traditional Chinese Medicine Hospital of Guangde City,Guangde,Anhui,242200,P.R.China;Department of Breast Surgery,First Affiliated Hospital of Anhui University of Traditional Chinese Medicine,Hefei,Anhui,230031,P.R.China)

机构地区：[1]广德市中医院甲状腺乳腺外科,安徽广德242200 [2]安徽中医药大学第一附属医院乳腺外科,安徽合肥230031

出　　处：《老年医学与保健》2024年第4期968-971,976,共5页Geriatrics & Health Care

摘　　要：目的本研究通过分析老年局部晚期乳腺癌患者根治术前实施重组人血管内皮抑制素联合EC-T序贯新辅助化疗的疗效及安全性,以期为临床诊疗提供方法。方法回顾性选取2015年1月—2022年9月在广德市中医院接受治疗的老年LABC患者80例作为研究对象,依据不同的治疗方法将患者分为观察组(n=40例)和对照组(n=40)。对照组根治术前应用EC-T序贯新辅助化疗,观察组在与对照组患者相同治疗的基础上加用重组人血管内皮抑制素。比较2组临床疗效、血清肿瘤标志物水平和不良反应。结果治疗后,观察组患者治疗有效率、疾病控制率分别高于对照组(75.00%vs 52.50%、92.50%vs 75.00%,P<0.05);观察组和对照组患者血清CA125、CEA水平相比同组治疗前均降低,且观察组血清CA125、CEA水平均低于对照组,差异均有统计学意义(均P<0.05)。治疗后对患者随访12个月,观察组患者生存率高于对照组(92.50%vs 72.50%,P<0.05)。观察组和对照组患者肝功能损害、白细胞减少、心功能损害、血小板减少、皮肤反应和胃肠道反应发生差异均无统计学意义(均P>0.05)。结论老年局部晚期乳腺癌根治术前实施重组人血管内皮抑制素联合EC-T序贯新辅助化疗,可提高患者的临床疗效,降低患者血清肿瘤标志物水平,而未增加患者的不良反应。Objective To analyze the efficacy and safety of recombinant human endostatin combined with EC-T sequential neoadjuvant chemotherapy before radical resection of locally advanced breast cancer(LABC)in elderly patients,and provide methods for clinical diagnosis and treatment.Methods A total of 80 elderly patients with LABC treated in Traditional Chinese Medicine Hospital of Guangde City from January 2015 to September 2022 were retrospectively selected.They were divided into observation group(40 cases)and control group(40 cases)according to different treatment methods.The control group was treated with EC-T sequential neoadjuvant chemotherapy before radical treatment,and the observation group was treated with recombinant human endostatin on the basis of the same treatment as the control group.The clinical efficacy,serum tumor marker level and adverse reactions were compared between the two groups.Results After treatment,the treatment effective rate and disease control rate of the observation group were higher than those of the control group(75.00%vs 52.50%,92.50%vs 75.00%,P<0.05).After treatment,the levels of serum CA125 and CEA of both groups were lower than those of the same group before treatment,and the observation group was lower than the control group(P<0.05).The patients were followed up for 12 months after treatment,and the survival rate of the observation group was higher than that of the control group(92.50%vs 72.50%,P<0.05).There were no significant differences in the incidence of liver function impairment,leukopenia,cardiac function impairment,thrombocytopenia,skin reaction and gastrointestinal reaction between the two groups(P>0.05).Conclusion The combination of recombinant human endostatin and EC-T sequential neoadjuvant chemotherapy before radical resection of locally advanced breast cancer can improve the clinical efficacy in elderly patients,reduce the levels of serum tumor markers,but not increase the adverse reactions of patients.

关 键 词：老年 晚期乳腺癌 重组人血管内皮抑制素 EC-T序贯化疗 临床疗效 

分 类 号：R737.9[医药卫生—肿瘤]